News

With the closing of the deal, MyoKardia now operates as a wholly-owned subsidiary of BMS. The deal provides BMS with MyoKardia’s mavacamten, which is a potential first-in-class cardiovascular

This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines. “We appreciate the collaboration with the UK Government as with

The status was based on efficacy and safety results from HPTN 083 phase IIb/III randomised, multicentre, double-blind and clinical trial. The study compared long-acting and injectable cabotegravir to

The study, IMPOWER 22, will evaluate the efficacy and safety of islatravir — Merck’s novel investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation for both treatment and

“There is a critical unmet need for people living with Wolfram syndrome, a rare genetic disease in which many patients die prematurely with severe neurological disabilities,” said Wolfram

The independent and NIH-appointed Data Safety Monitoring Board (DSMB) revealed that the mRNA-1273 candidate has demonstrated an efficacy rate of 94.5% in the first interim analysis of the

The phase 2 segment will evaluate the efficacy of Covid-19 DNA vaccine candidate called INO-4800 in adults in the US. Inovio’s study will be financed by the US

Dr. Himanshu Pop Hale, Ace Hospital Pune, India, has recruited the first patient in the IPF phase II Proof-of-Concept study with C21 (VP01 project). “We are pleased to announce that

As part of single target research collaboration, both companies will conduct research activities to select a pre-clinical candidate after which Roche will focus on further development and global